175 related articles for article (PubMed ID: 33019463)
1. Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
Liu Q; Chen D; Ye Z; Jin Z; Ma T; Huang X
Medicine (Baltimore); 2020 Oct; 99(40):e22542. PubMed ID: 33019463
[TBL] [Abstract][Full Text] [Related]
2. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
4. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
Uemura Y; Sone T; Tanaka S; Miyazaki T; Tsukiyama M; Taguchi A; Soen S; Mori S; Hagino H; Sugimoto T; Fukunaga M; Ohta H; Nakamura T; Orimo H; Shiraki M;
Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
[TBL] [Abstract][Full Text] [Related]
5. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.
Hagino H; Uemura Y; Mori S; Sone T; Ohta H; Nakamura T
J Bone Miner Metab; 2021 Jul; 39(4):668-677. PubMed ID: 33738617
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
8. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T
Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754
[TBL] [Abstract][Full Text] [Related]
9. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
Kumagai K; Harigane K; Kusayama Y; Tezuka T; Choe H; Inaba Y; Saito T
Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
[TBL] [Abstract][Full Text] [Related]
10. Overview of the clinical efficacy and safety of eldecalcitol for the treatment of osteoporosis.
Cui L; Xia W; Yu C; Dong S; Pei Y
Arch Osteoporos; 2022 May; 17(1):74. PubMed ID: 35513519
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
Yoshioka T; Okimoto N; Okamoto K; Sakai A
J Bone Miner Metab; 2013 Mar; 31(2):153-60. PubMed ID: 23076293
[TBL] [Abstract][Full Text] [Related]
12. Minodronate for the treatment of osteoporosis.
Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
[TBL] [Abstract][Full Text] [Related]
13. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
14. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
[TBL] [Abstract][Full Text] [Related]
16. Number and severity of prevalent vertebral fractures and the risk of subsequent vertebral fractures in Japanese women with osteoporosis: results from the minodronate trial.
Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Ohashi Y; Nakamura T; Matsumoto T
J Bone Miner Metab; 2013 Sep; 31(5):544-50. PubMed ID: 23529800
[TBL] [Abstract][Full Text] [Related]
17. Alendronate for the Treatment of Osteoporosis in Men: A Meta-Analysis of Randomized Controlled Trials.
Xu Z
Am J Ther; 2017; 24(2):e130-e138. PubMed ID: 27058577
[TBL] [Abstract][Full Text] [Related]
18. Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Sato Y; Honda Y; Iwamoto J; Amano N
J Musculoskelet Neuronal Interact; 2013 Sep; 13(3):346-52. PubMed ID: 23989256
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Serrano AJ; Begoña L; Anitua E; Cobos R; Orive G
Gynecol Endocrinol; 2013 Dec; 29(12):1005-14. PubMed ID: 24063695
[TBL] [Abstract][Full Text] [Related]
20. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
Soen S; Yamamoto K; Takeuchi T; Tanaka Y; Tanaka S; Ito M; Nakano T; Hagino H; Hirakawa A; Matsumoto T
J Bone Miner Metab; 2020 Jul; 38(4):511-521. PubMed ID: 31970477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
